Subscriber Benefit
As a subscriber you can listen to articles at work, in the car, or while you work out. Subscribe Now
Eli Lilly and Co. has filed lawsuits against 10 companies it accuses of selling unauthorized versions of its diabetes drug Mounjaro, Bloomberg News reported Tuesday.
The businesses in question include medical spas, wellness centers and compounding pharmacies in several states.
Four of the businesses are accused of selling compounded versions of Mounjaro, also known as tirzepatide, which Lilly said violates state laws because the drugs have not been approved by the U.S. Food and Drug Administration.
The remaining businesses are accused of selling knockoff versions of the drug under the Mounjaro name, resulting in trademark violations and false advertising.
“Lilly filed this lawsuit to protect patients,” the company said in a written statement. “Lilly cannot validate the safety or effectiveness of products claiming to contain tirzepatide that are not our own branded product. Because of this, Lilly filed lawsuits to protect patient safety and stop the unlawful marketing and sale of non-FDA approved compounded products.”
Mounjaro is expected to receive FDA approval for the treatment of obesity later this year.
Please enable JavaScript to view this content.